Clinical trial · Observational
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
NCT03964298CI-TRIAL-00093452imMUnocompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uveal Melanoma | Uveal Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Response rate Data collection of the efficacity of PD-1 inhibitors
- timeFrame
- December 2019
- description
- Description of Response rate
- measure
- Progression Free Survival Data collection of the efficacity of PD-1 inhibitors
- timeFrame
- December 2019
- description
- Description of PFS (Progression Free Survival)
- measure
- Global Survival Data collection of the efficacity of PD-1 inhibitors
- timeFrame
- December 2019
- description
- Description of Global Survival
- measure
- Stability Data collection of the efficacity of PD-1 inhibitors
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic uveal melanoma * Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment Exclusion Criteria: * Antecedent of another evolutionary tumor pathology
References
Publications (1)
- RESULTSaint-Ghislain M, Derrien AC, Geoffrois L, Gastaud L, Lesimple T, Negrier S, Penel N, Kurtz JE, Le Corre Y, Dutriaux C, Gardrat S, Barnhill R, Matet A, Cassoux N, Houy A, Ramtohul T, Servois V, Mariani P, Piperno-Neumann S, Stern MH, Rodrigues M. MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients. Eur J Cancer. 2022 Sep;173:105-112. doi: 10.1016/j.ejca.2022.06.033. Epub 2022 Jul 19. PMID 35863105